Wealthcare Advisory Partners’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Wealthcare Advisory Partners’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-45	Closed	-$2K	–	1424
2020 Q1	$2K	Hold	45	–	–	﹤0.01%	1337
2019 Q4	$3K	Hold	45	–	–	﹤0.01%	1222
2019 Q3	$3K	Hold	45	–	–	﹤0.01%	1178
2019 Q2	$3K	Hold	45	–	–	﹤0.01%	1159
2019 Q1	$2K	Hold	45	–	–	﹤0.01%	1121
2018 Q4	$2K	Hold	45	–	–	﹤0.01%	1105
2018 Q3	$3K	Hold	45	–	–	﹤0.01%	1093
2018 Q2	$3K	Hold	45	–	–	﹤0.01%	1090
2018 Q1	$2K	Hold	45	–	–	﹤0.01%	983
2017 Q4	$2K	Hold	45	–	–	﹤0.01%	945
2017 Q3	$3K	Buy	+45	New	+$2.72K	﹤0.01%	741

Other funds holding EGRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Wealthcare Advisory Partners's EGRX Position: Q2 2020 in Review

Wealthcare Advisory Partners sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2020, closing a stake of 45 shares — an estimated $2K sold.

Wealthcare Advisory Partners first reported a position in EGRX in Q3 2017 and held it in 11 quarters. The position peaked at $3K in Q4 2019. 164 funds tracked by Wall St. Rank hold EGRX as of Q2 2020.

Wealthcare Advisory Partners reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2020 after selling out during the quarter.
Wealthcare Advisory Partners sold 45 Eagle Pharmaceuticals, Inc. shares in Q2 2020, an estimated $2K.
Wealthcare Advisory Partners first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2017 and held it in 11 quarters.
Wealthcare Advisory Partners's Eagle Pharmaceuticals, Inc. position peaked at $3K in Q4 2019.
164 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2020.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2020, filed 29 Jul 2020.